Aaron G.L. Fletcher - Nov 22, 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc. (TFFP)

Role
Director
Signature
/s/ Aaron G.L. Fletcher, by Kirk Allen Coleman, as Attorney-in-Fact
Stock symbol
TFFP
Transactions as of
Nov 22, 2022
Transactions value $
$49,991
Form type
4
Date filed
11/23/2022, 06:59 AM
Previous filing
Nov 17, 2022
Next filing
Nov 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TFFP Common Stock Purchase $50K +43.5K +43.47% $1.15 143K Nov 22, 2022 Direct F3
holding TFFP Common Stock 110K Nov 22, 2022 See footnote F1
holding TFFP Common Stock 542K Nov 22, 2022 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TFFP Common Stock Purchase Warrants Purchase $0 +21.7K $0.00 21.7K Nov 22, 2022 Common Stock 21.7K $1.29 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund II, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund II, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F2 The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. Dr. Fletcher disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Dr. Fletcher is the beneficial owner of any securities covered by this Form 4.
F3 The reported shares were purchased in a private transaction from TFF Pharmaceuticals, Inc. at a price of $1.15.